Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

RAD001 for Patients With Radioiodine Refractory Thyroid Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Massachusetts General Hospital
M.D. Anderson Cancer Center
Mount Sinai Hospital, New York
Novartis
Information provided by (Responsible Party):
Jochen Lorch, MD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT00936858
First received: July 9, 2009
Last updated: January 8, 2016
Last verified: January 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: December 2016
  Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)